Celecoxib is not banned. It remains an FDA-approved prescription medication in the United States and is available in many other countries, including Canada and throughout Europe. The confusion likely stems from the fact that two closely related drugs, Vioxx and Bextra, were pulled from the market in 2004 and 2005 over serious safety concerns. Celecoxib (sold as Celebrex) survived that wave of withdrawals, but it did pick up significant restrictions and warnings that limit how and when it can be prescribed.
Why Vioxx and Bextra Were Pulled
Celecoxib belongs to a class of painkillers called COX-2 inhibitors, which were designed to reduce pain and inflammation while being gentler on the stomach than older anti-inflammatory drugs like ibuprofen or naproxen. Three COX-2 inhibitors reached the market in the early 2000s: rofecoxib (Vioxx), valdecoxib (Bextra), and celecoxib (Celebrex). Two of the three didn’t survive.
Vioxx was withdrawn from the market in September 2004 after data showed it significantly increased the risk of heart attacks and strokes. The withdrawal was one of the largest drug safety scandals in modern history, affecting tens of millions of patients worldwide.
Bextra followed in 2005. In a trial of 1,671 patients recovering from coronary artery bypass surgery, those taking Bextra experienced cardiovascular events at four times the rate of those on placebo (2% versus 0.5%). On top of the heart risks, Bextra was linked to severe, sometimes fatal skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. That combination of dangers led regulators to pull it from the market.
Why Celecoxib Stayed on the Market
Celecoxib carries some of the same cardiovascular risks as its now-banned relatives, but its safety profile turned out to be more favorable. The largest head-to-head comparison, known as the PRECISION trial, followed more than 24,000 arthritis patients for an average of nearly three years. It compared celecoxib directly against ibuprofen and naproxen, two of the most widely used over-the-counter painkillers.
The results were surprising. Celecoxib showed a significantly lower risk of combined heart and kidney events compared with ibuprofen, with a 33% relative reduction. It also trended toward lower risk than naproxen, though that comparison fell just short of statistical significance. Kidney problems specifically occurred at a rate of 0.52% with celecoxib versus 0.91% with ibuprofen during active treatment. In short, celecoxib performed at least as well as the common painkillers most people assume are safer.
That evidence gave regulators enough confidence to keep celecoxib available, though with heavy restrictions rather than an outright ban.
The Black Box Warning
Celecoxib carries the FDA’s most serious type of safety warning, printed in a black-bordered box at the top of its prescribing information. The warning covers two major risks.
- Heart attacks and strokes: All non-aspirin anti-inflammatory drugs, including celecoxib, increase the risk of serious cardiovascular events. This risk can appear early in treatment and grows with longer use.
- Stomach and intestinal bleeding: Celecoxib can cause bleeding, ulcers, or perforation anywhere in the digestive tract, sometimes without warning symptoms. Older adults and people with a history of ulcers face the highest risk.
These warnings apply to all prescription anti-inflammatory drugs, not just celecoxib. But the COX-2 class drew extra scrutiny after the Vioxx disaster, making the warnings particularly prominent for celecoxib.
Restrictions on Who Can Take It
Celecoxib is completely off-limits for certain groups. You cannot take it around the time of coronary artery bypass surgery, a restriction directly prompted by the data that helped sink Bextra. It’s also contraindicated if you have a known allergy to sulfonamide-type drugs, or if you’ve ever had asthma, hives, or an allergic reaction triggered by aspirin or another anti-inflammatory drug. Severe, rarely fatal allergic reactions have been reported in those patients.
Health Canada went further than the FDA in its guidance, recommending that celecoxib not be prescribed at all to people with existing cardiovascular disease, diabetes, or elevated heart risk. Canadian guidelines also recommend using the lowest effective dose for the shortest possible time, ideally only weeks rather than months.
How COX-2 Inhibitors Differ From Regular Painkillers
The body produces two versions of an enzyme called cyclooxygenase. The first version, COX-1, handles everyday housekeeping: protecting the stomach lining, supporting kidney function, and helping blood clot properly. The second version, COX-2, ramps up during inflammation and drives pain and swelling.
Older anti-inflammatory drugs like ibuprofen and naproxen block both versions, which is why they’re effective for pain but notorious for causing stomach problems. COX-2 inhibitors like celecoxib were engineered to target only the inflammation-related enzyme, sparing the stomach’s protective mechanisms. That design does deliver on its promise: celecoxib causes fewer gastrointestinal side effects, especially when combined with a stomach-protecting medication.
The tradeoff is cardiovascular risk. By blocking COX-2 without affecting COX-1, these drugs shift the body’s balance between blood clotting and blood vessel relaxation in a way that can promote clots. This is the core mechanism behind the heart attack and stroke risk that brought down Vioxx and Bextra, and that keeps celecoxib under tight regulatory scrutiny even though it remains available.
Current Status Worldwide
As of 2025, celecoxib remains on the FDA’s approved drug product list in the United States, where it’s available both as brand-name Celebrex and in generic form. It is also available in Canada, Europe, and many other countries, though with varying levels of restriction. The cardiovascular risk warnings are universal, and most regulatory agencies recommend the same approach: use the lowest dose that works, for the shortest time possible, and avoid it entirely if you have significant heart risk factors.
The drug was never banned, but the shadow of Vioxx and Bextra created a lasting public perception that all COX-2 inhibitors were pulled from the market. Celecoxib is the sole survivor of that class, and it stays on the market precisely because its risk profile, while real, proved manageable compared to the alternatives that were removed.